WO2011126810A2 - Intravaginal drug delivery device - Google Patents

Intravaginal drug delivery device Download PDF

Info

Publication number
WO2011126810A2
WO2011126810A2 PCT/US2011/030222 US2011030222W WO2011126810A2 WO 2011126810 A2 WO2011126810 A2 WO 2011126810A2 US 2011030222 W US2011030222 W US 2011030222W WO 2011126810 A2 WO2011126810 A2 WO 2011126810A2
Authority
WO
WIPO (PCT)
Prior art keywords
thermoplastic matrix
progestin
thermoplastic
drug delivery
hydrogen
Prior art date
Application number
PCT/US2011/030222
Other languages
French (fr)
Other versions
WO2011126810A3 (en
Inventor
Ze'ev Shaked
Klaus Nickisch
Jim Dinunzio
Feng Zhang
Marcelo Omelczuk
Original Assignee
Evestra, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Evestra, Inc. filed Critical Evestra, Inc.
Priority to RU2012146080A priority Critical patent/RU2648827C2/en
Priority to CN2011800219738A priority patent/CN103025320A/en
Priority to CA2798034A priority patent/CA2798034A1/en
Priority to JP2013502703A priority patent/JP5813093B2/en
Priority to AU2011238710A priority patent/AU2011238710B2/en
Priority to KR1020127028157A priority patent/KR101828619B1/en
Priority to EP11766436.7A priority patent/EP2552426A4/en
Publication of WO2011126810A2 publication Critical patent/WO2011126810A2/en
Publication of WO2011126810A3 publication Critical patent/WO2011126810A3/en
Priority to ZA2012/08185A priority patent/ZA201208185B/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A61K9/0036—Devices retained in the vagina or cervix for a prolonged period, e.g. intravaginal rings, medicated tampons, medicated diaphragms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F6/00—Contraceptive devices; Pessaries; Applicators therefor
    • A61F6/06—Contraceptive devices; Pessaries; Applicators therefor for use by females
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F6/00—Contraceptive devices; Pessaries; Applicators therefor
    • A61F6/06—Contraceptive devices; Pessaries; Applicators therefor for use by females
    • A61F6/08—Pessaries, i.e. devices worn in the vagina to support the uterus, remedy a malposition or prevent conception, e.g. combined with devices protecting against contagion
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones

Definitions

  • the present invention generally relates to drug delivery systems. More particularly, the invention relates to vaginal drug delivery systems, which release one or more active substances in a substantially constant ratio over a prolonged period of time.
  • Combined oral contraceptive pills (e.g., oral contraceptives that include a combination of a progestin and an estrogen component) were developed to inhibit normal fertility in women. Such pills inhibit follicular development and prevent ovulation as their primary mechanism of action. Combined oral contraceptive pills are favored over oral contraceptives that include a single dosage (e.g., a gestagen), due to a reduced incidence of breakthrough bleeding and various side effects.
  • a single dosage e.g., a gestagen
  • intravaginal delivery provides good adsorption of active agents while avoiding the first-pass effect in the liver.
  • intravaginal delivery has been considered an efficacious method for administering many types of active agents.
  • Intravaginally administered active agents can directly diffuse through the vaginal tissues to provide a local effect or a systemic effect, thereby treating numerous conditions within and outside the vaginal and/or urogenital tract, such as hormonal dysfunctions, inflammation, infection, pain, and incontinence.
  • vaginal delivery systems capable of releasing two or more therapeutically active substances at a substantially constant rate to one another over a prolonged period of time are, for example, useful for certain applications. In particular, such devices would be useful for contraception and hormone replacement therapy.
  • a number of intravaginal delivery systems have been proposed but all tend to suffer from being relatively complicated, making them more expensive to manufacture.
  • an intravaginal drug delivery device comprises an uncoated thermoplastic matrix; and a progestin dispersed in the thermoplastic matrix.
  • the progestin compound is etonogestrel.
  • the progestin compound is levonorgestrel.
  • the device has a substantially annular form. The device may deliver an effective amount of the progestin for at least 30 days.
  • thermoplastic matrix further comprises an estrogen compound dispersed in the thermoplastic matrix.
  • the estrogen compound is N-(2-aminoethyl)
  • the estrogen compound is a nitrated estrogen derivative.
  • the thermoplastic matrix comprises an ethylene vinyl acetate copolymer.
  • the thermoplastic matrix may also be composed of one or more hydrophilic matrix materials and/or one or more hydrophobic matrix materials.
  • the thermoplastic matrix comprises an ethyl vinyl acetate copolymer and one or more hydrophilic matrix materials.
  • the thermoplastic matrix includes one or more functional excipients.
  • functional excipients include pore forming components and
  • thermoplastic matrix including, but not limited to, antifungal compounds, and antiprogestins.
  • a method of making an intravaginal drug delivery device includes forming a mixture of a thermoplastic polymer and a progestin; heating the thermoplastic polymer/progestin mixture such that at least a portion of the thermoplastic polymer is softened or melted to form a heated mixture of thermoplastic polymer and progestin; and permitting the heated mixture to solidify as a solid mass, h one embodiment, the heated mixture is placed in a mold to form the solid mass.
  • the method further includes blending an estrogen compound with the progestin and the thermoplastic polymer.
  • the estrogen compound in one embodiment, is ethinylestradiol. In another embodiment, the estrogen compound is a nitrated estrogen derivative.
  • an intravaginal drug delivery device includes a thermoplastic matrix, a progestin dispersed in the thermoplastic matrix; wherein the concentration of progestin dispersed in the thermoplastic matrix is greater than about 6 times the saturation concentration for the progestin in the thermoplastic matrix; and an estrogen dispersed in the thermoplastic matrix.
  • an intravaginal drug delivery device comprises a thermoplastic matrix, a progestin dispersed in the thermoplastic matrix; and an estrogen dispersed in the thermoplastic matrix; wherein the thermoplastic matrix has a non-annular geometry that allows controlled release of the progestin and the estrogen over a predetermined number of days.
  • Non- annular geometries include, but are not limited to a strand of geometrically shaped segments linked together or a half torus.
  • a method of producing a contraceptive state in a subject includes positioning any intravaginal device, as described above, in the vagina or uterus of a female.
  • FIG. 1 depicts an intravaginal drug delivery device having an annular geometry
  • FIG. 2 depicts an intravaginal drug delivery device having a geometry in the form of a strand of geometrically shaped segments linked together;
  • FIG. 3 depicts an intravaginal drug delivery device having a half-oval geometry
  • FIG. 4 depicts an intravaginal drug delivery device having a hollow cylindrical geometry
  • FIG. 5 depicts an intravaginal drug delivery device having a monolithic film geometry. While the invention may be susceptible to various modifications and alternative forms, specific embodiments thereof are shown by way of example in the drawings and will herein be described in detail. The drawings may not be to scale. It should be understood, however, that the drawings and detailed description thereto are not intended to limit the invention to the particular form disclosed, but to the contrary, the intention is to cover all modifications, equivalents, and alternatives falling within the spirit and scope of the present invention as defined by the appended claims. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
  • an "intravaginal device” refers to an object that provides for
  • an active agent to the vaginal and/or urogenital tract of a subject, including, e.g., the vagina, cervix, or uterus of a female.
  • an intravaginal drug delivery device includes an uncoated thermoplastic matrix, a progestin dispersed in the thermoplastic matrix.
  • a progestin dispersed in the thermoplastic matrix.
  • an estrogen may also be dispersed in the thermoplastic matrix.
  • thermoplastic matrix A variety of materials may be used as the thermoplastic matrix.
  • the materials used in the intravaginal device of are suitable for extended placement in the vaginal tract or the uterus.
  • a thermoplastic material used to form the intravaginal drug delivery device is nontoxic and non-absorbable in the subject.
  • the intravaginal drug delivery device may be formed from a biodegradable material.
  • the materials may be suitably shaped and have a flexibility allowing for intravaginal administration.
  • Suitable materials for use in the formation of an intravaginal drug delivery device include, but are not limited to: polysiloxanes (e.g., poly(dimethyl siloxane); copolymers of dimethylsiloxanes and methylvinylsiloxanes; ethylene/vinyl acetate copolymers (EVA); polyethylene; polypropylene; ethylene/propylene copolymers; acrylic acid polymers; ethylene/ethyl acrylate copolymers; polytetrafluoroethylene (PTFE); polyurethanes; polyesters; polybutadiene; polyisoprene; poly(methacrylate); polymethyl methacrylate; styrene-butadiene- styrene block copolymers; poly(hydroxyethylmethacrylate) (pHEMA); polyvinyl chloride; polyvinyl acetate; polyethers; polyacrylonitriles; polyethylene glycols; polymethylpentene;
  • an intravaginal drug delivery device is formed from an ethylene/vinyl acetate copolymer (EVA).
  • EVA ethylene/vinyl acetate copolymer
  • grades may be used including grades having a low melt index, a high melt index, a low vinyl acetate content or a high vinyl acetate content.
  • EVA having a "low melt index” has a melt index of less than about 100 g/10 min as measured using ASTM test 1238.
  • EVA having a "high melt index” has a melt index of greater than about 100 g/10 min as measured using ASTM test 1238.
  • EVA having a "low vinyl acetate content” has a vinyl acetate content of less than about 20% by weight.
  • EVA having a "high vinyl acetate content” has a vinyl acetate content of greater than about 20% by weight.
  • the thermoplastic matrix of an intravaginal drug delivery device may be formed from EVA having a low melt index, a high melt index, a low vinyl acetate content or a high vinyl acetate content.
  • the thermoplastic matrix may include: mixtures of a low melt index and high melt index EVA or mixtures of low vinyl acetate content and high vinyl acetate content EVA.
  • thermoplastic matrix a combination of one or more suitable materials may be used to form the thermoplastic matrix.
  • the material(s) may be selected to allow prolonged release of the active ingredients from the thermoplastic matrix without the need for an outer controlled release coating.
  • concentration of the active agents, in combination with the matrix material maybe selected to provide the desired effect.
  • the thermoplastic matrix may be composed of ethyl vinyl acetate copolymer in combination with a hydrophobic polymer.
  • a matrix material is considered to be hydrophobic or water-insoluble if it is “sparingly soluble” or “practically insoluble” or “insoluble” as defined by USP 29 / F 24.
  • hydrophobic polymers include, but are not limited to acrylic acid-based polymers, methacrylic acid based polymers, and acrylic acid - methacrylic acid based copolymers.
  • acrylic acid-based polymers refers to any polymer that includes one or more repeating units that include and/or are derived from acrylic acid.
  • methacrylic acid-based polymers refers to any polymer that includes one or more repeating units that include and/or are derived from methacrylic acid.
  • Derivatives of acrylic acid and methacrylic acid include, but are not limited to, alkyl ester derivatives, alkylether ester derivatives, amide derivatives, alkyl amine derivatives, anhydride derivatives, cyanoalkyl derivatives, and amino-acid derivatives.
  • acrylic acid-based polymers, methacrylic acid based polymers, and acrylic acid - methacrylic acid based copolymers include, but are nor limited to to Eudragit® LI 00, Eudragit® LI 00-55, Eudragit® L 30 D-55, Eudragit® SI 00, Eudragit® 4135F, Eudragit® RS, acrylic acid and methacrylic acid copolymers, methyl methacrylate polymers, methyl methacrylate copolymers, polyethoxyethyl methacrylate, polycyano ethyl methacrylate, aminoalkyl methacrylate copolymer, polyacrylic acid, polymethacrylic acid, methacrylic acid alkylamine copolymer, polymethyl methacrylate, polymethacrylic acid anhydride, polyalkylmethacrylate, polyacrylamide, and polymethacrylic acid anhydride and glycidyl methacrylate copolymers.
  • hydrophobic polymers include, but are not limited to, alkylcelluloses such as ethylcellulose, calcium carboxyrnethyl cellulose, certain substituted cellulose polymers such as hydroxypropyl methylcellulose phthalate, and hydroxypropyl methylcellulose acetate succinate, cellulose acetate butyrate, cellulose acetate phthalate, and cellulose acetate trimaleate, polyvinyl acetate phthalate, polyvinyl acetate, polyester, shellac, zein, or the like.
  • alkylcelluloses such as ethylcellulose, calcium carboxyrnethyl cellulose
  • certain substituted cellulose polymers such as hydroxypropyl methylcellulose phthalate, and hydroxypropyl methylcellulose acetate succinate, cellulose acetate butyrate, cellulose acetate phthalate, and cellulose acetate trimaleate
  • polyvinyl acetate phthalate polyvinyl acetate
  • polyester shellac,
  • the thermoplastic matrix may be composed of ethyl vinyl acetate copolymer in combination with a hydrophilic polymer.
  • a matrix material is considered hydrophilic and a polymer is considered to be water-soluble if it is more than sparingly soluble as defined by USP 29 / NF 24, that is if according to USP 29 / NF 24 the matrix material or polymer is classified as "soluble” or "very soluble.”
  • the hydrophilic polymer preferably is from about 1% to about 50% of the thermoplastic matrix material by weight, more preferably less than about 30%, less than about 20%; or less than about 10% of the thermoplastic matrix by weight.
  • hydrophilic polymers include, but are not limited to polyethylene oxide (PEO), ethylene oxide-propylene oxide co-polymers, polyethylene-polypropylene glycol (e.g. poloxamer), carbomer, polycarbopbil, chitosan, polyvinyl pyrrolidone (PVP), polyvinyl alcohol (PVA), hydroxyalkyl celluloses such as hydroxypropyl cellulose (HPC), hydroxyethyl cellulose (HEC), hydroxymethyl cellulose and hydroxypropyl methylcellulose (HPMC), carboxyrnethyl cellulose, sodium carboxyrnethyl cellulose, methylcellulose, hydroxyethyl methylcellulose, hydroxypropyl methylcellulose, polyacrylates such as carbomer, polyacrylamides, polymethacrylamides, polyphosphazines, polyoxazolidines, polyhydroxyalkylcarboxylic acids, alginic acid and its derivatives such as carrageenate alginates
  • the thermoplastic matrix may include one or more biodegradable polymers.
  • biodegradable polymers include, but are not limited to, polylactic acid (PLA), polyglycolic acid (PGA), polyglycolic lactic acid (PGLA), and polycaprolactone.
  • the active agents for example the progestin and, optionally, the estrogen are dispersed in the thermoplastic matrix.
  • dispersed with respect to a polymer matrix, means that a compound is substantially evenly distributed through the polymer, either as a solid suspension in the polymer or dissolved within the polymer matrix.
  • particle dispersion refers to a suspension of the compound particles homogenously distributed in the polymer.
  • molecular dispersion refers to the dissolution of the compound in the polymer.
  • a dispersion may be characterized as a particle dispersion if particles of the compound are visible in the polymer at a magnification of about 100X under regular and polarized light.
  • a molecular dispersion is characterized as a dispersion in which substantially no particles of the compound are visible in the polymer at a magnification of 100X under regular and polarized light.
  • one or more functional excipients may be incorporated into the thermoplastic matrix.
  • excipients include, but are not limited to antioxidants, buffering agents, alkalinizing agents, disintegrants, chelating agents, colorants, surfactants, solubilizers, wetting agents, stabilizers, waxes, lipophilic materials, absorption enhancers, preservatives, absorbents, cross-linking agents, bioadhesive polymers, retardants, pore formers, osmotic agents and fragrance
  • one or more pore forming components may be dispersed in the thermoplastic matrix.
  • Exemplary pore forming components include binders such as lactose, calcium sulfate, calcium phosphate and the like; salts such as sodium chloride, magnesium chloride and the like, poloxamers and combinations thereof and other similar or equivalent materials which are widely known in the art.
  • the intravaginal drug delivery device is used to produce a contraceptive state in a female mammal.
  • the contraceptive state may be produced by administering an intravaginal drug delivery device that includes a progestin.
  • contraceptive state may be produced by administering an intravaginal drug delivery device that includes a progestin and an estrogen component.
  • progestin refers to a progestogen, a progestational substance, or any pharmaceutically acceptable substance in the steroid art that generally possesses progestational activity including synthetic steroids that have progestational activity.
  • Progestins suitable for use may be of natural or synthetic origin.
  • Progestins include, but are not limited to: 17a-17-hydroxy- 1 l-methylene-19-norpregna-4,15-dien-20-yn-3-one, 17a-ethynyl-19-nortestosterone, 17a- ethynyltestosterone, 17-deacetylnorgestimate, 19-nor-17-hydroxyprogesterone, 19- norprogesterone, 3 -hydroxydesogestrel, 3-ketodesogestrel (etonogestrel), acetoxypregnenolone, algestone acetophenide, allylestrenol, amgestone, anagestone acetate, chlormadinone, chlormadinone acetate, cyproterone, cyproterone acetate, d-17P-acetoxy-13 -ethyl-17a- ethynylgon-4-en-3-one oxime, demegestone, desogestrel, die
  • estrogen refers to any of various natural or synthetic compounds that stimulate the development of female secondary sex characteristics and promote the growth and maintenance of the female reproductive system, or any other compound that mimics the physiological effect of natural estrogens. Estrogens also include compounds that can be converted to active estrogenic compounds in the uterine environment.
  • Estrogens include, but are not limited to, estradiol (17 -estradiol), estridiol acetate, estradiol benzoate, estridiol cypionate, estridiol decanoate, estradiol diacetate, estradiol heptanoate, estradiol valerate, 17a-estradiol, estriol, estriol succinate, estrone, estrone acetate, estrone sulfate, estropipate (piperazine estrone sulfate), ethynylestradiol (17a-ethynylestradiol, ethinyl estradiol, ethinyl estradiol, ethynyl estradiol), ethynylestradiol 3-acetate, ethynylestradiol 3-benzoate, mestranol, quinestrol, and nitrated estrogen derivatives.
  • Nitrated estrogen derivatives are described in U.S. Patent No. 5,554,603 to Kim et al. which is incorporated herein by reference.
  • Nitrated estrogen derivatives that may be used in combination with a progestin include compounds having the structure:
  • R 1 is hydrogen, Q-Cs alkyl, cycloalkyl, or Ci-C 8 acyl
  • R 2 is hydrogen or Ci-Cs alkyl
  • R 3 is hydrogen, hydroxy or -Cg alkyl
  • R4 is hydrogen or Ci-C 8 alkyl
  • each R 5 and R 6 is, independently, hydrogen or nitrate; and wherein at least one of R 5 and R 6 is a nitrate group.
  • the nitrated estrogen derivative has the structure:
  • Ri is hydrogen, Q-Cg alkyl, cycloalkyl, or Ci-Cg acyl
  • R 2 is hydrogen or C Cg alkyl
  • R 3 is hydrogen, hydroxy or Ci-Cg alkyl
  • R4 is hydrogen or C C 8 alkyl
  • each R 5 and R 6 is, independently, hydrogen or nitrate; and wherein at least one of R 5 and R 6 is a nitrate group.
  • a specific compound that may be used in combination with a progestin in an oral contraceptive to inhibit ovulation in a female subject includes the compound (+)-3,11 ⁇ ,17 ⁇ - trihydroxyestra-l,3,5(10)-triene 3 -acetate- 11,17-dinitrate ester, which has the structure:
  • antiprogestins are compounds that act as progesterone antagonists. Such compounds may be particular useful as contraceptives as well as for the treatment of various types of cancers. If incorporated into an intravaginal drug delivery device, such compounds may help treat cancers such as cervical cancer or breast cancers.
  • antiprogestins include, but are not limited to, Mifepristone, Onapristone, ORG-33628, Proellex, and Lonaprisan (ZK-230211).
  • exemplary progesterone antagonists that may be incorporated into the intravaginal drug delivery device include compounds havin the structure:
  • R 1 is a hydrogen atom, a straight-chain C C 5 alkyl group, a branched C C 5 alkyl group, a C 3 -C 5 cycloalkyl group, or a halogen atom
  • R 2 is a hydrogen atom, a straight-chain Q-C5 alkyl group a branched C1-C5 alkyl group, a C 3 -C 5 cycloalkyl group, or a halogen atom; or
  • R 1 and R 2 together are a methylene group
  • R J is a hydrogen atom, a straight-chain C1-C5 alkyl group a branched Q-C5 alkyl group, a C 3 -C 5 cycloalkyl group, or a halogen atom;
  • R 4 is a hydrogen atom, a straight-chain Q-C5 alkyl group a branched Q-C5 alkyl group, a C 3 -C 5 cycloalkyl group, or a halogen atom; or
  • R 3 and R 4 together are an additional bond or a methylene group
  • R 5 is a radical Y or an aryl radical that is optionally substituted with Y, wherein Y is a hydrogen atom, a halogen atom, -OR 6 , -N0 2 , -N 3 , -CN, -NR 6a R 6b , -NHS0 2 R 6 , -C0 2 R 6 , Cj-C 10 alkyl, C Cio substituted alkyl, Q-Cio cycloalkyl, Ci-Cio alkenyl, Ci-C 10 alkynyl, Q-C10 alkoxy, Cr C 10 alkanoyloxy, benzoyloxy, arylacyl, Ci-C 10 -alkylacyl, Ci-Cio-cycloalkylacyl, CrC 10 hydroxyalkyl, aryl or arylalkyl, a five or six membered heterocyclic radical containing up to three heteroatoms;
  • R 6a and R 6b are the same or different and represent a hydrogen atom or a Ci-C ⁇ alkyl group, R 6 is a hydrogen atom or Ci-Cw alkyl,
  • Y when Y is a -NR 6a R 6b radical, Y may be in the form of a physiologically compatible salt formed by reaction of an acid;
  • R 6 when Y is -C0 2 R 6 , R 6 may represent a cation of a physiologically compatible salts formed by reaction with a base;
  • the wavy lines represent that the substituent can be in an a- or ⁇ -orientation.
  • antifungal compounds include, but are not limited to polyene antifungals such as natamycin, rimocidin, filipin, nystatin, amphotericin B, candicin, and hamycin; imidazole antifungals such as miconazole (Micatin®), ketoconazole (Nizoral®, Fungoral® and Sebizole®), clotrimazole (Lotrimin®, Lotrimin AF® and Canesten®), econazole, omoconazole, bifonazole, butoconazole, fenticonazole, isoconazole, oxiconazole, sertaconazole (Ertaczo®), sulconazole, and tioconazole; triazole antifungals such as fluconazole, itraconazole, isavuconazole, ravuconazole, posaconazole, voriconazole, terconazole,
  • antifungal properties include, but are not limited to polygodial, benzoic acid, ciclopirox, tolnaftate (Tinactin®, Desenex® and Aftate®), undecylenic acid, flucytosine or 5-fluorocytosine, griseofulvin, and haloprogin.
  • antibiotic compounds include but are not limited to ⁇ -lactam antibiotics such as benzathine penicillin, benzylpenicillin (penicillin G), phenoxymethylpenicillin (penicillin V), procaine penicillin, methicillin, oxacillin, nafcillin, cloxacillin, dicloxacillin, fiucloxacillin, temocillin, amoxicillin, ampicillin, co-amoxiclav (amoxicillin+clavulanic acid), azlocillin, carbenicillin, ticarcillin, mezlocillin, piperacillin, cephalosporin, cephalexin, cephalothin, cefazolin, cefaclor, cefuroxime, cefamandole, cefotetan, cefoxitin, ceftriaxone, cefotaxime, cefpodoxime, cefixime, ceftazidime, cefepime, cefpirome, carbaper
  • sulfonamides such as sulfamethoxazole, sulfisomidine (also known as sulfaisodimidine), sulfacetamide, sulfadoxine, dichlorphenamide (DCP), and dorzolamide; quinolone antibiotics such as cinobac, flumequine, nalidixic acid, oxolinic acid, piromidic acid, pipemidic acid, rosoxacin, ciprofloxacin, enoxacin, fleroxacin, lomefloxacin, nadiiloxacin, norfloxacin, ofloxacin, pefloxacin, rufloxacin, balofloxacin, grepafloxacin, levofloxacin, pazufloxacin, spaxfloxacin, temafloxacin, tosufloxacin, clinafloxacin, gatifloxacin, gemifloxacin,
  • the intravaginal delivery device can be in any shape suitable for insertion and retention in the vaginal tract without causing undue discomfort to the user.
  • the intravaginal device may be flexible.
  • "flexible” refers to the ability of an intravaginal drug delivery device to bend or withstand stress and strain without being damaged or broken.
  • an intravaginal may be deformed or flexed, such as, for example, using finger pressure, and upon removal of the pressure, return to its original shape.
  • the flexible properties of the intravaginal drug delivery device are useful for enhancing user comfort, and also for ease of administration to the vaginal tract and/or removal of the device from the vaginal tract.
  • the intravaginal drug delivery device may be annular in shape.
  • annular refers to a shape of, relating to, or forming a ring. Annular shapes suitable for use include a ring, an oval, an ellipse, a toroid, and the like.
  • the intravaginal drug delivery device is a vaginal ring, as depicted in FIG. 1.
  • the intravaginal drag delivery device may have a non-annular geometry. Examples of non-annular geometries are depicted in FIGS. 2-4.
  • the thermoplastic matrix used to form the intravaginal drug delivery device has a geometry in the form of a strand of geometrically shaped segments linked together.
  • a plurality of hexagon shaped units may be linked to form a strand.
  • Other geometrically shaped units including, but not limited to, squares, triangles, rectangles, pentagons, heptagons, octagons, etc. maybe formed into strands.
  • mixtures of different geometrically shaped units may be joined to together in a strand.
  • the strand of geometrically shaped units may be joined together to form ring-like structure.
  • FIG. 3 depicts another embodiment of an intravaginal drug delivery device in the shape of a half oval.
  • a half oval device may be easier to manufacture than a full ring.
  • the half oval shape may allow a user to form a ring like structure before and/or after insertion.
  • FIG. 4 depicts another embodiment of an intravaginal drug delivery device in the shape of a hollow cylinder. Use of a hollow cylinder may allow easier insertion of the intravaginal delivery device.
  • the hollow cylinder geometry may allow insertion of the intravaginal drug delivery device into the vaginal tract in a compressed form, which, upon deployment, expands inside the tract to improve the retention of the device.
  • FIG. 5 depicts a monolithic film geometry. Such a film may be formed or include, mucoadhesive substances to improve adhesion to the vaginal tract.
  • the intravaginal drag delivery device may be manufactured by any known techniques.
  • therapeutically active agent(s) may be mixed within the thermoplastic matrix material and processed to the desired shape by: injection molding, rotation/injection molding, casting, extrusion, or other appropriate methods.
  • the intravaginal drag delivery device is produced by a hot-melt extrusion process.
  • a method of making an intravaginal drug delivery device includes: a. forming a mixture of a thermoplastic polymer and a progestin;
  • thermoplastic polymer/progestin mixture such that at least a portion of the thermoplastic polymer is softened or melted to form a heated mixture of thermoplastic polymer and progestin;
  • a mixture is “softened” or “melted” by applying thermal or mechanical energy sufficient to render the mixture partially or substantially completely molten.
  • “melting” the mixture may include substantially melting the matrix material without substantially melting one or more other materials present in the mixture (e.g., the therapeutic agent and one or more excipients).
  • a "softened” or “melted” polymer is a polymer that is heated to a temperature at or above the glass transition temperature of the polymer.
  • a mixture is sufficiently melted or softened, when it can be extruded as a continuous rod, or when it can be subjected to injection molding.
  • thermoplastic polymer and the progestin can be produced using any suitable means.
  • Well-known mixing means known to those skilled in the art include dry mixing, dry granulation, wet granulation, melt granualation, high shear mixing, and low shear mixing.
  • Granulation generally is the process wherein particles of powder are made to adhere to one another to form granules, typically in the size range of 0.2 to 4.0 mm. Granulation is desirable in pharmaceutical formulations because it produces relatively homogeneous mixing of different sized particles.
  • Dry granulation involves aggregating powders with high compressional loads.
  • Wet granulation involves forming granules using a granulating fluid including either water, a solvent such as alcohol or water/solvent blend, where this solvent agent is subsequently removed by drying.
  • Melt granulation is a process in which powders are transformed into solid aggregates or agglomerates while being heated. It is similar to wet granulation except that a binder acts as a wetting agent only after it has melted. The granulation is further achieved following using milling and/or screening to obtain the desired particle sizes or ranges. All of these and other methods of mixing pharmaceutical formulations are well-known in the art.
  • the mixture of thermoplastic polymer and the progestin is softened or melted to produce a mass sufficiently fluid to permit shaping of the mixture and/or to produce melding of the components of the mixture.
  • the softened or melted mixture is then permitted to solidify as a substantially solid mass.
  • the mixture can optionally be shaped or cut into suitable sizes during the softening or melting step or during the solidifying step. In some embodiments, the mixture becomes a homogeneous mixture either prior to or during the softening or melting step.
  • Methods of melting and molding the mixture include, but are not limited to, hot-melt extrusion, injection molding and compression molding.
  • Hot-melt extrusion typically involves the use of an extruder device.
  • extruder devices are well-known in the art.
  • Such systems include mechanisms for heating the mixture to an appropriate temperature and forcing the melted feed material under pressure through a die to produce a rod, sheet or other desired shape of constant cross-section.
  • the extrudate can be cut into smaller sizes appropriate for use as an oral dosage form.
  • Any suitable cutting device known to those skilled in the art can be used, and the mixture can be cut into appropriate sizes either while still at least somewhat soft or after the extrudate has solidified.
  • the extrudate may be cut, ground or otherwise shaped to a shape and size appropriate to the desired oral dosage form prior to solidification, or may be cut, ground or otherwise shaped after solidification.
  • an oral dosage form may be made as a non-compressed hot-melt extrudate.
  • an oral dosage form is not in the form of a compressed tablet.
  • Injection molding typically involves the use of an injection-molding device. Such devices are well-known in the art. Injection molding systems force a melted mixture into a mold of an appropriate size and shape. The mixture solidifies as least partially within the mold and then is released.
  • Compression molding typically involves the use of an compression-molding device. Such devices are well-known in the art. Compression molding is a method in which the mixture is optionally preheated and then placed into a heated mold cavity. The mold is closed and pressure is applied. Heat and pressure are typically applied until the molding material is cured. The molded oral dosage form is then released from the mold.
  • the final step in the process of making intravaginal drug delivery device is permitting the mixture to solidify as a solid mass.
  • the mixture may optionally be shaped either prior to solidification or after solidification. Solidification will generally occur either as a result of cooling of the melted mixture or as a result of curing of the mixture however any suitable method for producing a solid dosage form may be used.
  • the intravaginal drug delivery device includes a progestin as a substantially uniform dispersion within the thermoplastic matrix.
  • the distribution of the progestin within the thermoplastic matrix can be substantially non-uniform.
  • One method of producing a non-uniform distribution of the progestin is through the use of one or more coatings of water-insoluble or water-soluble polymer.
  • Another method is by providing two or more mixtures of polymer or polymer and progestin to different zones of a compression or injection mold. These methods are provided by way of example and are not exclusive. Other methods of producing a non-uniform distribution of therapeutic agent within the abuse-deterring oral dosage forms will be apparent to those skilled in the art.
  • an annular intravaginal drug delivery device has an outer ring diameter from 35 mm to 70 mm, from 35 mm to 60 mm, from 45 mm to 65 mm, or from 50 mm to 60 mm.
  • the cross sectional diameter may be from 1 mm to 10 mm, from 2 mm to 6 mm, from 3.0 mm to 5.5 mm, from 3.5 mm to 4.5 mm, or from 4.0 mm to 5.0 mm.
  • the amount of active agent released from the intravaginal drug delivery device maybe determined by a qualified healthcare professional and is dependent on many factors, e.g., the active agent, the condition to be treated, the age and/or weight of the subject to be treated, etc.
  • the active agent is released from the device at an average rate of about 0.01 mg to about 10 mg per 24 hours in situ, or about 0.05 mg to about 5 mg per 24 hours in situ, or about 0.1 mg to about 1 mg per 24 hours in situ. In some embodiments, the active agent is released from the device at an average rate of about 1 mg to about 100 mg per 24 hours in situ or about 5 mg to about 50 mg per 24 hours in situ.
  • two or more active agents can be released from the device at a different rate per 24 hours in situ.
  • an estrogen can be released from the device at an average rate of about 0.01 mg to about 0.1 mg per 24 hours and a progestin can be released from the device at an average rate of about 0.08 mg to about 0.2 mg per 24 hours in situ, or an estrogen can be released from the device at an average rate of about 0.1 mg to about 1 mg per 24 hours in situ and a progestin can be released from the device at an average rate of about 0.05 mg to about 5 mg per 24 hours in situ, or an estrogen can be released from the device at an average rate of about 0.05 mg to about 5 mg per 24 hours in situ and a progestin can be released from the device at an average rate of about 1 mg to about 100 mg per 24 hours in situ.
  • the release rate can be measured in vitro using, e.g., the USP Apparatus Paddle 2 method.
  • the active agent(s) can be assayed by methods known in the art, e.g., by HPLC.
  • active agent(s) is/are released from the intravaginal device at a steady rate for up to about 1 month or about 30 days after administration to a female, for up to about 25 days after administration to a female, for up to about 21 days after administration to a female, for up to about 15 days after administration to a female, for up to about 10 days after administration to a female, for up to about 7 days after administration to a female, or for up to about 4 days after administration to a female.
  • a "steady rate” is a release rate that does not vary by an amount greater than 70% of the amount of active agent released per 24 hours in situ, by an amount greater than 60% of the amount of active agent released per 24 hours in situ, by an amount greater than 50% of the amount of active agent released per 24 hours in situ, by an amount greater than 40%) of the amount of active agent released per 24 hours in situ, by an amount greater than 30%> of the amount of active agent released per 24 hours in situ, by an amount greater than 20% of the amount of active agent released per 24 hours in situ, by an amount greater than 10% of the amount of active agent released per 24 hours in situ, or by an amount greater than 5% of the amount of active agent released per 24 hours in situ
  • the active agent is a progestin with a steady release rate of active agent in situ of about 80 ⁇ g to about 200 ⁇ g per 24 hours, about 90 ⁇ g to about 150 ⁇ g per 24 hours, about 90 ⁇ g to about 125 ⁇ g per 24 hours, or about 95 ⁇ g
  • the active agent includes an estrogen with a steady release rate of active agent in situ of about 10 ⁇ g to about 100 ⁇ g per 24 hours, about 10 ⁇ g to about 80 ⁇ g per 24 hours, about 10 ⁇ g to about 60 ⁇ g per 24 hours, about 10 ⁇ g to about 40 ⁇ g per 24 hours, about 10 g to about 20 ⁇ g per 24 hours, or about 10 ⁇ g to about 15 ⁇ g per 24 hours.
  • an intravaginal drug delivery device that includes progestin without an estrogen has advantages over combined progestin/estrogen devices. Some women are unable to tolerate estrogen. For example, women that are breast feeding are unable to take contraceptives that include estrogen. For such women, use of an intravaginal drug delivery device that includes only a progestin would offer a safe solution to the desire to have effective birth control while being unable to take estrogen containing formulations.
  • a progestin and an estrogen are embedded into an ethylene vinyl acetate (EVA) matrix using a melt extruder, using the levels provided in formulation Table 1 below:
  • composition is extruded as a flat monolithic sheet that and provides surface area necessary for sustained release of both drug substances over a period of 21 days when measured by drug release in a volumetric flask in pH 7.4 phosphate buffer.
  • a progestin was embedded into an ethylene vinyl acetate (EVA) matrix using a melt extruder, using the levels provided in formulation Table 1 below:
  • composition is extruded and molded into a ring.
  • the resulting device is an uncoated ring of progesterone in an EVA matrix.
  • the ring delivered the progestin over a period of 21 days when measured by drug release in a volumetric flask in pH 7.4 phosphate buffer.
  • a progestin and an estrogen are embedded into an ethylene vinyl acetate (EVA) matrix using a melt extruder. Additional pore forming agents were incorporated using the levels provided in formulation Table 2 below:
  • composition is extruded as a flat monolithic sheet that and provides surface area necessary for sustained release of both drug substances over a period of 21 days when measured by drug release in a volumetric flask in pH 7.4 phosphate buffer.
  • a progestin and estrogen are embedded into an ethylene vinyl acetate (EVA) matrix using a melt extruder. Additional pore forming agents were incorporated using the levels provided in formulation Table 3 below:
  • composition is extruded as a flat monolithic sheet that and provides surface area necessary for sustained release of both drug substances over a period of 21 days when measured by drug release in a volumetric flask in pH 7.4 phosphate buffer.

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Reproductive Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Gynecology & Obstetrics (AREA)
  • Biomedical Technology (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Diabetes (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Described herein is an intravaginal drug delivery system. In an embodiment the intravaginal drug delivery system includes a progestin and estrogen compound, and releases the active ingredients in a fixed physiological ratio over a prolonged period of time to produce a contraceptive state in a female.

Description

TITLE: INTRA VAGINAL DRUG DELIVERY DEVICE
BACKGROUND OF THE INVENTION
1. Field of the Invention
The present invention generally relates to drug delivery systems. More particularly, the invention relates to vaginal drug delivery systems, which release one or more active substances in a substantially constant ratio over a prolonged period of time.
2. Description of the Relevant Art
Combined oral contraceptive pills, (e.g., oral contraceptives that include a combination of a progestin and an estrogen component) were developed to inhibit normal fertility in women. Such pills inhibit follicular development and prevent ovulation as their primary mechanism of action. Combined oral contraceptive pills are favored over oral contraceptives that include a single dosage (e.g., a gestagen), due to a reduced incidence of breakthrough bleeding and various side effects.
Many of the side effects associated with oral contraceptive pills are due to the use of hormones to regulate the reproductive functions of women. Some of the potential side effects include: depression, vaginal discharge, changes in menstrual flow, breakthrough bleeding, nausea, vomiting, headaches, changes in the breasts, changes in blood pressure, loss of scalp hair, skin problems and skin improvements, increased risk of deep venous thrombosis (DVT) and pulmonary embolism, stroke and myocardial infarction (heart attack). The incidence of various side effects appears to be related, to some extent, on the dosage of both the gestagen and estrogen components. By minimizing the amount of one or both of these compounds administered many of the known side effects may be reduced or eliminated.
In some instances intravaginal delivery provides good adsorption of active agents while avoiding the first-pass effect in the liver. As a result, intravaginal delivery has been considered an efficacious method for administering many types of active agents. Intravaginally administered active agents can directly diffuse through the vaginal tissues to provide a local effect or a systemic effect, thereby treating numerous conditions within and outside the vaginal and/or urogenital tract, such as hormonal dysfunctions, inflammation, infection, pain, and incontinence. Because of the rapid absorption of active agents through the vaginal tissues, and the avoidance of first pass liver and gastric modifications of the active agents, administration of active agents, particularly hormones, through the vaginal tissues may reduce or eliminate some of the side effects associated with oral adrninistration of hormones. Vaginal delivery systems capable of releasing two or more therapeutically active substances at a substantially constant rate to one another over a prolonged period of time are, for example, useful for certain applications. In particular, such devices would be useful for contraception and hormone replacement therapy. A number of intravaginal delivery systems have been proposed but all tend to suffer from being relatively complicated, making them more expensive to manufacture.
There is a need in the art for improved intravaginal devices capable of delivering active agents to the uterus or vaginal space, with the devices having increased physical integrity, safety, and comfort.
SUMMARY OF THE INVENTION
In one embodiment, an intravaginal drug delivery device comprises an uncoated thermoplastic matrix; and a progestin dispersed in the thermoplastic matrix. In one embodiment, the progestin compound is etonogestrel. In another embodiment, the progestin compound is levonorgestrel. In one embodiment, the device has a substantially annular form. The device may deliver an effective amount of the progestin for at least 30 days.
In some embodiments, the thermoplastic matrix further comprises an estrogen compound dispersed in the thermoplastic matrix. In one embodiment, the estrogen compound is
ethinylestradiol. In an embodiment, the estrogen compound is a nitrated estrogen derivative.
In some embodiments, the thermoplastic matrix comprises an ethylene vinyl acetate copolymer. The thermoplastic matrix may also be composed of one or more hydrophilic matrix materials and/or one or more hydrophobic matrix materials. In an embodiment, the thermoplastic matrix comprises an ethyl vinyl acetate copolymer and one or more hydrophilic matrix materials.
In some embodiments, the thermoplastic matrix includes one or more functional excipients. Examples of functional excipients include pore forming components and
biodegradable polymer. Additional active agents may be present in the thermoplastic matrix including, but not limited to, antifungal compounds, and antiprogestins.
In an embodiment, a method of making an intravaginal drug delivery device includes forming a mixture of a thermoplastic polymer and a progestin; heating the thermoplastic polymer/progestin mixture such that at least a portion of the thermoplastic polymer is softened or melted to form a heated mixture of thermoplastic polymer and progestin; and permitting the heated mixture to solidify as a solid mass, h one embodiment, the heated mixture is placed in a mold to form the solid mass. In one embodiment, the method further includes blending an estrogen compound with the progestin and the thermoplastic polymer. The estrogen compound, in one embodiment, is ethinylestradiol. In another embodiment, the estrogen compound is a nitrated estrogen derivative.
In an embodiment, an intravaginal drug delivery device includes a thermoplastic matrix, a progestin dispersed in the thermoplastic matrix; wherein the concentration of progestin dispersed in the thermoplastic matrix is greater than about 6 times the saturation concentration for the progestin in the thermoplastic matrix; and an estrogen dispersed in the thermoplastic matrix.
In another embodiment, an intravaginal drug delivery device comprises a thermoplastic matrix, a progestin dispersed in the thermoplastic matrix; and an estrogen dispersed in the thermoplastic matrix; wherein the thermoplastic matrix has a non-annular geometry that allows controlled release of the progestin and the estrogen over a predetermined number of days. Non- annular geometries include, but are not limited to a strand of geometrically shaped segments linked together or a half torus.
A method of producing a contraceptive state in a subject includes positioning any intravaginal device, as described above, in the vagina or uterus of a female.
BRIEF DESCRIPTION OF THE DRAWINGS
Advantages of the present invention will become apparent to those skilled in the art with the benefit of the following detailed description of embodiments and upon reference to the accompanying drawings in which:
FIG. 1 depicts an intravaginal drug delivery device having an annular geometry;
FIG. 2 depicts an intravaginal drug delivery device having a geometry in the form of a strand of geometrically shaped segments linked together;
FIG. 3 depicts an intravaginal drug delivery device having a half-oval geometry;
FIG. 4 depicts an intravaginal drug delivery device having a hollow cylindrical geometry; and
FIG. 5 depicts an intravaginal drug delivery device having a monolithic film geometry. While the invention may be susceptible to various modifications and alternative forms, specific embodiments thereof are shown by way of example in the drawings and will herein be described in detail. The drawings may not be to scale. It should be understood, however, that the drawings and detailed description thereto are not intended to limit the invention to the particular form disclosed, but to the contrary, the intention is to cover all modifications, equivalents, and alternatives falling within the spirit and scope of the present invention as defined by the appended claims. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
It is to be understood the present invention is not limited to particular devices, which may, of course, vary. It is also to be understood that the terminology used herein is for the purpose of describing particular embodiments only, and is not intended to be lirniting. As used in this specification and the appended claims, the singular forms "a", "an", and "the" include singular and plural referents unless the content clearly dictates otherwise. Thus, for example, reference to "a progestin" includes one or more progestins.
As used herein, an "intravaginal device" refers to an object that provides for
administration or application of an active agent to the vaginal and/or urogenital tract of a subject, including, e.g., the vagina, cervix, or uterus of a female.
In an embodiment, an intravaginal drug delivery device includes an uncoated thermoplastic matrix, a progestin dispersed in the thermoplastic matrix. Optionally, an estrogen may also be dispersed in the thermoplastic matrix.
A variety of materials may be used as the thermoplastic matrix. Generally, the materials used in the intravaginal device of are suitable for extended placement in the vaginal tract or the uterus. In an embodiment, a thermoplastic material used to form the intravaginal drug delivery device is nontoxic and non-absorbable in the subject. In other embodiments, the intravaginal drug delivery device may be formed from a biodegradable material. In some embodiments, the materials may be suitably shaped and have a flexibility allowing for intravaginal administration.
Suitable materials for use in the formation of an intravaginal drug delivery device include, but are not limited to: polysiloxanes (e.g., poly(dimethyl siloxane); copolymers of dimethylsiloxanes and methylvinylsiloxanes; ethylene/vinyl acetate copolymers (EVA); polyethylene; polypropylene; ethylene/propylene copolymers; acrylic acid polymers; ethylene/ethyl acrylate copolymers; polytetrafluoroethylene (PTFE); polyurethanes; polyesters; polybutadiene; polyisoprene; poly(methacrylate); polymethyl methacrylate; styrene-butadiene- styrene block copolymers; poly(hydroxyethylmethacrylate) (pHEMA); polyvinyl chloride; polyvinyl acetate; polyethers; polyacrylonitriles; polyethylene glycols; polymethylpentene; polybutadiene; polyhydroxy alkanoates; poly(lactic acid); poly(glycolic acid); polyanhydrides; polyorthoesters; hydrophilic hydrogels; cross-linked polyvinyl alcohol; neoprene rubber; butyl rubber; or mixtures thereof.
In an embodiment, an intravaginal drug delivery device is formed from an ethylene/vinyl acetate copolymer (EVA). A variety of grades may be used including grades having a low melt index, a high melt index, a low vinyl acetate content or a high vinyl acetate content. As used herein, EVA having a "low melt index" has a melt index of less than about 100 g/10 min as measured using ASTM test 1238. EVA having a "high melt index" has a melt index of greater than about 100 g/10 min as measured using ASTM test 1238. EVA having a "low vinyl acetate content" has a vinyl acetate content of less than about 20% by weight. EVA having a "high vinyl acetate content" has a vinyl acetate content of greater than about 20% by weight. The thermoplastic matrix of an intravaginal drug delivery device may be formed from EVA having a low melt index, a high melt index, a low vinyl acetate content or a high vinyl acetate content. In some embodiments, the thermoplastic matrix may include: mixtures of a low melt index and high melt index EVA or mixtures of low vinyl acetate content and high vinyl acetate content EVA.
In an embodiment, a combination of one or more suitable materials may be used to form the thermoplastic matrix. The material(s) may be selected to allow prolonged release of the active ingredients from the thermoplastic matrix without the need for an outer controlled release coating. In addition, the concentration of the active agents, in combination with the matrix material maybe selected to provide the desired effect.
In one embodiment, the thermoplastic matrix may be composed of ethyl vinyl acetate copolymer in combination with a hydrophobic polymer. For purposes of the present disclosure a matrix material is considered to be hydrophobic or water-insoluble if it is "sparingly soluble" or "practically insoluble" or "insoluble" as defined by USP 29 / F 24.
Examples of hydrophobic polymers include, but are not limited to acrylic acid-based polymers, methacrylic acid based polymers, and acrylic acid - methacrylic acid based copolymers. As used herein, the phrase "acrylic acid-based polymers" refers to any polymer that includes one or more repeating units that include and/or are derived from acrylic acid. As used herein, the phrase "methacrylic acid-based polymers" refers to any polymer that includes one or more repeating units that include and/or are derived from methacrylic acid. Derivatives of acrylic acid and methacrylic acid include, but are not limited to, alkyl ester derivatives, alkylether ester derivatives, amide derivatives, alkyl amine derivatives, anhydride derivatives, cyanoalkyl derivatives, and amino-acid derivatives. Examples of acrylic acid-based polymers, methacrylic acid based polymers, and acrylic acid - methacrylic acid based copolymers include, but are nor limited to to Eudragit® LI 00, Eudragit® LI 00-55, Eudragit® L 30 D-55, Eudragit® SI 00, Eudragit® 4135F, Eudragit® RS, acrylic acid and methacrylic acid copolymers, methyl methacrylate polymers, methyl methacrylate copolymers, polyethoxyethyl methacrylate, polycyano ethyl methacrylate, aminoalkyl methacrylate copolymer, polyacrylic acid, polymethacrylic acid, methacrylic acid alkylamine copolymer, polymethyl methacrylate, polymethacrylic acid anhydride, polyalkylmethacrylate, polyacrylamide, and polymethacrylic acid anhydride and glycidyl methacrylate copolymers. Further examples of hydrophobic polymers include, but are not limited to, alkylcelluloses such as ethylcellulose, calcium carboxyrnethyl cellulose, certain substituted cellulose polymers such as hydroxypropyl methylcellulose phthalate, and hydroxypropyl methylcellulose acetate succinate, cellulose acetate butyrate, cellulose acetate phthalate, and cellulose acetate trimaleate, polyvinyl acetate phthalate, polyvinyl acetate, polyester, shellac, zein, or the like.
In one embodiment, the thermoplastic matrix may be composed of ethyl vinyl acetate copolymer in combination with a hydrophilic polymer. For purposes of the present disclosure, a matrix material is considered hydrophilic and a polymer is considered to be water-soluble if it is more than sparingly soluble as defined by USP 29 / NF 24, that is if according to USP 29 / NF 24 the matrix material or polymer is classified as "soluble" or "very soluble." When used in the thermoplastic matrix material the hydrophilic polymer preferably is from about 1% to about 50% of the thermoplastic matrix material by weight, more preferably less than about 30%, less than about 20%; or less than about 10% of the thermoplastic matrix by weight.
Examples of hydrophilic polymers include, but are not limited to polyethylene oxide (PEO), ethylene oxide-propylene oxide co-polymers, polyethylene-polypropylene glycol (e.g. poloxamer), carbomer, polycarbopbil, chitosan, polyvinyl pyrrolidone (PVP), polyvinyl alcohol (PVA), hydroxyalkyl celluloses such as hydroxypropyl cellulose (HPC), hydroxyethyl cellulose (HEC), hydroxymethyl cellulose and hydroxypropyl methylcellulose (HPMC), carboxyrnethyl cellulose, sodium carboxyrnethyl cellulose, methylcellulose, hydroxyethyl methylcellulose, hydroxypropyl methylcellulose, polyacrylates such as carbomer, polyacrylamides, polymethacrylamides, polyphosphazines, polyoxazolidines, polyhydroxyalkylcarboxylic acids, alginic acid and its derivatives such as carrageenate alginates, ammonium alginate and sodium alginate, starch and starch derivatives, polysaccharides, carboxypolymethylene, polyethylene glycol, , natural gums such as gum guar, gum acacia, gum tragacanth, karaya gum and gum xanthan, povidone, gelatin or the like.
In some embodiments, the thermoplastic matrix may include one or more biodegradable polymers. Examples of biodegradable polymers include, but are not limited to, polylactic acid (PLA), polyglycolic acid (PGA), polyglycolic lactic acid (PGLA), and polycaprolactone.
In an embodiment, the active agents, for example the progestin and, optionally, the estrogen are dispersed in the thermoplastic matrix. As used herein the term "dispersed", with respect to a polymer matrix, means that a compound is substantially evenly distributed through the polymer, either as a solid suspension in the polymer or dissolved within the polymer matrix. The term "particle dispersion," as used herein refers to a suspension of the compound particles homogenously distributed in the polymer. The term "molecular dispersion," as used herein refers to the dissolution of the compound in the polymer. For purposes of this disclosure, a dispersion may be characterized as a particle dispersion if particles of the compound are visible in the polymer at a magnification of about 100X under regular and polarized light. A molecular dispersion is characterized as a dispersion in which substantially no particles of the compound are visible in the polymer at a magnification of 100X under regular and polarized light.
In addition to the thermoplastic matrix and one or more therapeutic agents, one or more functional excipients may be incorporated into the thermoplastic matrix. Examples of excipients include, but are not limited to antioxidants, buffering agents, alkalinizing agents, disintegrants, chelating agents, colorants, surfactants, solubilizers, wetting agents, stabilizers, waxes, lipophilic materials, absorption enhancers, preservatives, absorbents, cross-linking agents, bioadhesive polymers, retardants, pore formers, osmotic agents and fragrance
In one embodiment, one or more pore forming components may be dispersed in the thermoplastic matrix. Exemplary pore forming components include binders such as lactose, calcium sulfate, calcium phosphate and the like; salts such as sodium chloride, magnesium chloride and the like, poloxamers and combinations thereof and other similar or equivalent materials which are widely known in the art.
In an embodiment, the intravaginal drug delivery device is used to produce a contraceptive state in a female mammal. The contraceptive state may be produced by administering an intravaginal drug delivery device that includes a progestin. In other embodiments, contraceptive state may be produced by administering an intravaginal drug delivery device that includes a progestin and an estrogen component.
As used herein, a "progestin" refers to a progestogen, a progestational substance, or any pharmaceutically acceptable substance in the steroid art that generally possesses progestational activity including synthetic steroids that have progestational activity. Progestins suitable for use may be of natural or synthetic origin. Progestins include, but are not limited to: 17a-17-hydroxy- 1 l-methylene-19-norpregna-4,15-dien-20-yn-3-one, 17a-ethynyl-19-nortestosterone, 17a- ethynyltestosterone, 17-deacetylnorgestimate, 19-nor-17-hydroxyprogesterone, 19- norprogesterone, 3 -hydroxydesogestrel, 3-ketodesogestrel (etonogestrel), acetoxypregnenolone, algestone acetophenide, allylestrenol, amgestone, anagestone acetate, chlormadinone, chlormadinone acetate, cyproterone, cyproterone acetate, d-17P-acetoxy-13 -ethyl-17a- ethynylgon-4-en-3-one oxime, demegestone, desogestrel, dienogest, dihydrogesterone, dimethisterone, drospirenone, dydrogesterone, ethisterone (pregneninolone, 17a- ethynyltestosterone), ethynodiol diacetate, fluorogestone acetate, gastrinone, gestadene, gestodene, gestonorone, gestrinone, hydroxymethylprogesterone, hydroxymethylprogesterone acetate, hydroxyprogesterone, hydroxyprogesterone acetate, hydroxyprogesterone caproate, levonorgestrel (1-norgestrol), lynestrenol (lynoestrenol), mecirogestone, medrogestone, medroxyprogesterone, medroxyprogesterone acetate, megestrol, megestrol acetate, melengestrol, melengestrol acetate, nestorone, nomegestrol, norelgestromin, norethindrone (norethisterone) (19-nor-17a-ethynyltestosterone), norethindrone acetate (norethisterone acetate), norethynodrel, norgestimate, norgestrel (d-norgestrel and dl-norgestrel), norgestrienone, normethisterone, progesterone, promegestone, quingestanol, tibolone, and trimegestone. In some embodiments, the progestin is progesterone, etonogestrel, levonorgestrel, gestodene, norethisterone, drospirenone, or combinations thereof.
As used herein, an "estrogen" refers to any of various natural or synthetic compounds that stimulate the development of female secondary sex characteristics and promote the growth and maintenance of the female reproductive system, or any other compound that mimics the physiological effect of natural estrogens. Estrogens also include compounds that can be converted to active estrogenic compounds in the uterine environment. Estrogens include, but are not limited to, estradiol (17 -estradiol), estridiol acetate, estradiol benzoate, estridiol cypionate, estridiol decanoate, estradiol diacetate, estradiol heptanoate, estradiol valerate, 17a-estradiol, estriol, estriol succinate, estrone, estrone acetate, estrone sulfate, estropipate (piperazine estrone sulfate), ethynylestradiol (17a-ethynylestradiol, ethinyl estradiol, ethinyl estradiol, ethynyl estradiol), ethynylestradiol 3-acetate, ethynylestradiol 3-benzoate, mestranol, quinestrol, and nitrated estrogen derivatives.
Nitrated estrogen derivatives are described in U.S. Patent No. 5,554,603 to Kim et al. which is incorporated herein by reference. Nitrated estrogen derivatives that may be used in combination with a progestin include compounds having the structure:
Figure imgf000010_0001
where R1 is hydrogen, Q-Cs alkyl, cycloalkyl, or Ci-C8 acyl;
R2 is hydrogen or Ci-Cs alkyl;
R3 is hydrogen, hydroxy or -Cg alkyl;
R4 is hydrogen or Ci-C8 alkyl;
where each R5 and R6 is, independently, hydrogen or nitrate; and wherein at least one of R5 and R6 is a nitrate group.
In some embodiments, the nitrated estrogen derivative has the structure:
Figure imgf000011_0001
where Ri is hydrogen, Q-Cg alkyl, cycloalkyl, or Ci-Cg acyl;
R2 is hydrogen or C Cg alkyl;
R3 is hydrogen, hydroxy or Ci-Cg alkyl;
R4 is hydrogen or C C8 alkyl;
where each R5 and R6 is, independently, hydrogen or nitrate; and wherein at least one of R5 and R6 is a nitrate group.
A specific compound that may be used in combination with a progestin in an oral contraceptive to inhibit ovulation in a female subject includes the compound (+)-3,11β,17β- trihydroxyestra-l,3,5(10)-triene 3 -acetate- 11,17-dinitrate ester, which has the structure:
Other active agents may be incorporated into the intravaginal drug delivery device including antiprogestins, antibiotics, and antifungal compounds. As used herein "antiprogestins" are compounds that act as progesterone antagonists. Such compounds may be particular useful as contraceptives as well as for the treatment of various types of cancers. If incorporated into an intravaginal drug delivery device, such compounds may help treat cancers such as cervical cancer or breast cancers. Examples, of antiprogestins include, but are not limited to, Mifepristone, Onapristone, ORG-33628, Proellex, and Lonaprisan (ZK-230211).
Other antiprogestins that may be incorporated into the intravaginal drag delivery device include antiprogestins that are described in U.S. Patent Application Publication No. 2010/0273759 entitled "Progesterone Antagonists", which is incorporated herein by reference. Exemplary progesterone antagonists that may be incorporated into the intravaginal drug delivery device include compounds havin the structure:
Figure imgf000011_0002
In which
R1 is a hydrogen atom, a straight-chain C C5 alkyl group, a branched C C5 alkyl group, a C3-C5 cycloalkyl group, or a halogen atom; R2 is a hydrogen atom, a straight-chain Q-C5 alkyl group a branched C1-C5 alkyl group, a C3-C5 cycloalkyl group, or a halogen atom; or
R1 and R2 together are a methylene group;
RJ is a hydrogen atom, a straight-chain C1-C5 alkyl group a branched Q-C5 alkyl group, a C3-C5 cycloalkyl group, or a halogen atom;
R4 is a hydrogen atom, a straight-chain Q-C5 alkyl group a branched Q-C5 alkyl group, a C3-C5 cycloalkyl group, or a halogen atom; or
R3 and R4 together are an additional bond or a methylene group;
R5 is a radical Y or an aryl radical that is optionally substituted with Y, wherein Y is a hydrogen atom, a halogen atom, -OR6, -N02, -N3, -CN, -NR6aR6b, -NHS02R6, -C02R6, Cj-C10 alkyl, C Cio substituted alkyl, Q-Cio cycloalkyl, Ci-Cio alkenyl, Ci-C10 alkynyl, Q-C10 alkoxy, Cr C10 alkanoyloxy, benzoyloxy, arylacyl, Ci-C10-alkylacyl, Ci-Cio-cycloalkylacyl, CrC10 hydroxyalkyl, aryl or arylalkyl, a five or six membered heterocyclic radical containing up to three heteroatoms;
R6a and R6b are the same or different and represent a hydrogen atom or a Ci-C^ alkyl group, R6 is a hydrogen atom or Ci-Cw alkyl,
when Y is a -NR6aR6b radical, Y may be in the form of a physiologically compatible salt formed by reaction of an acid;
when Y is -C02R6, R6 may represent a cation of a physiologically compatible salts formed by reaction with a base; and
the wavy lines represent that the substituent can be in an a- or β-orientation.
Examples of antifungal compounds include, but are not limited to polyene antifungals such as natamycin, rimocidin, filipin, nystatin, amphotericin B, candicin, and hamycin; imidazole antifungals such as miconazole (Micatin®), ketoconazole (Nizoral®, Fungoral® and Sebizole®), clotrimazole (Lotrimin®, Lotrimin AF® and Canesten®), econazole, omoconazole, bifonazole, butoconazole, fenticonazole, isoconazole, oxiconazole, sertaconazole (Ertaczo®), sulconazole, and tioconazole; triazole antifungals such as fluconazole, itraconazole, isavuconazole, ravuconazole, posaconazole, voriconazole, terconazole, and albaconazole; thiazole antifungals such as abafangin; allylamine antifungals such as terbinafine (Lamisil®), naftifine (Naftin®), and butenafine (Lotrimin Ultra®); and echinocandin antifungals such as anidulafungin, caspofungin, and micafungin. Other compounds that have antifungal properties include, but are not limited to polygodial, benzoic acid, ciclopirox, tolnaftate (Tinactin®, Desenex® and Aftate®), undecylenic acid, flucytosine or 5-fluorocytosine, griseofulvin, and haloprogin. Examples of antibiotic compounds include but are not limited to β-lactam antibiotics such as benzathine penicillin, benzylpenicillin (penicillin G), phenoxymethylpenicillin (penicillin V), procaine penicillin, methicillin, oxacillin, nafcillin, cloxacillin, dicloxacillin, fiucloxacillin, temocillin, amoxicillin, ampicillin, co-amoxiclav (amoxicillin+clavulanic acid), azlocillin, carbenicillin, ticarcillin, mezlocillin, piperacillin, cephalosporin, cephalexin, cephalothin, cefazolin, cefaclor, cefuroxime, cefamandole, cefotetan, cefoxitin, ceftriaxone, cefotaxime, cefpodoxime, cefixime, ceftazidime, cefepime, cefpirome, carbapenem, imipenem (with cilastatin), meropenem, ertapenem, faropenem, doripenem, aztreonam (Azactam®), tigemonam, nocardicin A, tabtoxinine-P-lactam, clavulanic acid, tazobactam, and sulbactam; Aminoglycoside antibiotics such as aminoglycoside, amikacin, apramycin, arbekacin, astromicin, bekanamycin, capreomycin, dibekacin, dihydrostreptomycin, elsamitrucin, G418, gentamicin, hygromycin B, isepamicin, kanamycin, kasugamycin, micronomicin, neomycin, netilmicin, paromomycin sulfate, ribostamycin, sisomicin, streptoduocin, streptomycin, tobramycin, verdamicin;
sulfonamides such as sulfamethoxazole, sulfisomidine (also known as sulfaisodimidine), sulfacetamide, sulfadoxine, dichlorphenamide (DCP), and dorzolamide; quinolone antibiotics such as cinobac, flumequine, nalidixic acid, oxolinic acid, piromidic acid, pipemidic acid, rosoxacin, ciprofloxacin, enoxacin, fleroxacin, lomefloxacin, nadiiloxacin, norfloxacin, ofloxacin, pefloxacin, rufloxacin, balofloxacin, grepafloxacin, levofloxacin, pazufloxacin, spaxfloxacin, temafloxacin, tosufloxacin, clinafloxacin, gatifloxacin, gemifloxacin, moxifloxacin, sitafloxacin, trovafloxacin, prulifloxacin, garenoxacin, and delafloxacin; and oxazolidone antibiotics such as linezolid, torezolid, eperezolid, posizolid, and radezolid.
The intravaginal delivery device can be in any shape suitable for insertion and retention in the vaginal tract without causing undue discomfort to the user. For example, the intravaginal device may be flexible. As used herein, "flexible" refers to the ability of an intravaginal drug delivery device to bend or withstand stress and strain without being damaged or broken. For example, an intravaginal may be deformed or flexed, such as, for example, using finger pressure, and upon removal of the pressure, return to its original shape. The flexible properties of the intravaginal drug delivery device are useful for enhancing user comfort, and also for ease of administration to the vaginal tract and/or removal of the device from the vaginal tract.
In an embodiment, the intravaginal drug delivery device may be annular in shape. As used herein, "annular" refers to a shape of, relating to, or forming a ring. Annular shapes suitable for use include a ring, an oval, an ellipse, a toroid, and the like. In some embodiments, the intravaginal drug delivery device is a vaginal ring, as depicted in FIG. 1. The intravaginal drag delivery device may have a non-annular geometry. Examples of non-annular geometries are depicted in FIGS. 2-4. In one embodiment, the thermoplastic matrix used to form the intravaginal drug delivery device has a geometry in the form of a strand of geometrically shaped segments linked together. For example, as shown in FIG. 1 a plurality of hexagon shaped units may be linked to form a strand. Other geometrically shaped units including, but not limited to, squares, triangles, rectangles, pentagons, heptagons, octagons, etc. maybe formed into strands. In some embodiment, mixtures of different geometrically shaped units may be joined to together in a strand. The strand of geometrically shaped units may be joined together to form ring-like structure.
FIG. 3 depicts another embodiment of an intravaginal drug delivery device in the shape of a half oval. A half oval device may be easier to manufacture than a full ring. In an
embodiment, the half oval shape may allow a user to form a ring like structure before and/or after insertion. FIG. 4 depicts another embodiment of an intravaginal drug delivery device in the shape of a hollow cylinder. Use of a hollow cylinder may allow easier insertion of the intravaginal delivery device. The hollow cylinder geometry may allow insertion of the intravaginal drug delivery device into the vaginal tract in a compressed form, which, upon deployment, expands inside the tract to improve the retention of the device. FIG. 5 depicts a monolithic film geometry. Such a film may be formed or include, mucoadhesive substances to improve adhesion to the vaginal tract.
The intravaginal drag delivery device may be manufactured by any known techniques.
In some embodiments, therapeutically active agent(s) may be mixed within the thermoplastic matrix material and processed to the desired shape by: injection molding, rotation/injection molding, casting, extrusion, or other appropriate methods. In one embodiment, the intravaginal drag delivery device is produced by a hot-melt extrusion process.
In one embodiment, a method of making an intravaginal drug delivery device includes: a. forming a mixture of a thermoplastic polymer and a progestin;
b. heating the thermoplastic polymer/progestin mixture such that at least a portion of the thermoplastic polymer is softened or melted to form a heated mixture of thermoplastic polymer and progestin; and;
c. permitting the heated mixture to cool and solidify as a solid mass,
d. and optionally, shaping the mass into a predetermined geometry.
For purposes of the present disclosure a mixture is "softened" or "melted" by applying thermal or mechanical energy sufficient to render the mixture partially or substantially completely molten. For instance, in a mixture that includes a matrix material, "melting" the mixture may include substantially melting the matrix material without substantially melting one or more other materials present in the mixture (e.g., the therapeutic agent and one or more excipients). For polymers, a "softened" or "melted" polymer is a polymer that is heated to a temperature at or above the glass transition temperature of the polymer. Generally, a mixture is sufficiently melted or softened, when it can be extruded as a continuous rod, or when it can be subjected to injection molding.
The mixture of the thermoplastic polymer and the progestin can be produced using any suitable means. Well-known mixing means known to those skilled in the art include dry mixing, dry granulation, wet granulation, melt granualation, high shear mixing, and low shear mixing.
Granulation generally is the process wherein particles of powder are made to adhere to one another to form granules, typically in the size range of 0.2 to 4.0 mm. Granulation is desirable in pharmaceutical formulations because it produces relatively homogeneous mixing of different sized particles.
Dry granulation involves aggregating powders with high compressional loads. Wet granulation involves forming granules using a granulating fluid including either water, a solvent such as alcohol or water/solvent blend, where this solvent agent is subsequently removed by drying. Melt granulation is a process in which powders are transformed into solid aggregates or agglomerates while being heated. It is similar to wet granulation except that a binder acts as a wetting agent only after it has melted. The granulation is further achieved following using milling and/or screening to obtain the desired particle sizes or ranges. All of these and other methods of mixing pharmaceutical formulations are well-known in the art.
Subsequent or simultaneous with mixing, the mixture of thermoplastic polymer and the progestin is softened or melted to produce a mass sufficiently fluid to permit shaping of the mixture and/or to produce melding of the components of the mixture. The softened or melted mixture is then permitted to solidify as a substantially solid mass. The mixture can optionally be shaped or cut into suitable sizes during the softening or melting step or during the solidifying step. In some embodiments, the mixture becomes a homogeneous mixture either prior to or during the softening or melting step. Methods of melting and molding the mixture include, but are not limited to, hot-melt extrusion, injection molding and compression molding.
Hot-melt extrusion typically involves the use of an extruder device. Such devices are well-known in the art. Such systems include mechanisms for heating the mixture to an appropriate temperature and forcing the melted feed material under pressure through a die to produce a rod, sheet or other desired shape of constant cross-section. Subsequent to or simultaneous with being forced through the die the extrudate can be cut into smaller sizes appropriate for use as an oral dosage form. Any suitable cutting device known to those skilled in the art can be used, and the mixture can be cut into appropriate sizes either while still at least somewhat soft or after the extrudate has solidified. The extrudate may be cut, ground or otherwise shaped to a shape and size appropriate to the desired oral dosage form prior to solidification, or may be cut, ground or otherwise shaped after solidification. In some embodiments, an oral dosage form may be made as a non-compressed hot-melt extrudate. In other embodiments, an oral dosage form is not in the form of a compressed tablet.
Injection molding typically involves the use of an injection-molding device. Such devices are well-known in the art. Injection molding systems force a melted mixture into a mold of an appropriate size and shape. The mixture solidifies as least partially within the mold and then is released.
Compression molding typically involves the use of an compression-molding device. Such devices are well-known in the art. Compression molding is a method in which the mixture is optionally preheated and then placed into a heated mold cavity. The mold is closed and pressure is applied. Heat and pressure are typically applied until the molding material is cured. The molded oral dosage form is then released from the mold.
The final step in the process of making intravaginal drug delivery device is permitting the mixture to solidify as a solid mass. The mixture may optionally be shaped either prior to solidification or after solidification. Solidification will generally occur either as a result of cooling of the melted mixture or as a result of curing of the mixture however any suitable method for producing a solid dosage form may be used.
In preferred embodiments, the intravaginal drug delivery device includes a progestin as a substantially uniform dispersion within the thermoplastic matrix. However in alternative embodiments the distribution of the progestin within the thermoplastic matrix can be substantially non-uniform. One method of producing a non-uniform distribution of the progestin is through the use of one or more coatings of water-insoluble or water-soluble polymer. Another method is by providing two or more mixtures of polymer or polymer and progestin to different zones of a compression or injection mold. These methods are provided by way of example and are not exclusive. Other methods of producing a non-uniform distribution of therapeutic agent within the abuse-deterring oral dosage forms will be apparent to those skilled in the art.
In practice, for a human female, an annular intravaginal drug delivery device has an outer ring diameter from 35 mm to 70 mm, from 35 mm to 60 mm, from 45 mm to 65 mm, or from 50 mm to 60 mm. The cross sectional diameter may be from 1 mm to 10 mm, from 2 mm to 6 mm, from 3.0 mm to 5.5 mm, from 3.5 mm to 4.5 mm, or from 4.0 mm to 5.0 mm. The amount of active agent released from the intravaginal drug delivery device maybe determined by a qualified healthcare professional and is dependent on many factors, e.g., the active agent, the condition to be treated, the age and/or weight of the subject to be treated, etc. Γη some embodiments, the active agent is released from the device at an average rate of about 0.01 mg to about 10 mg per 24 hours in situ, or about 0.05 mg to about 5 mg per 24 hours in situ, or about 0.1 mg to about 1 mg per 24 hours in situ. In some embodiments, the active agent is released from the device at an average rate of about 1 mg to about 100 mg per 24 hours in situ or about 5 mg to about 50 mg per 24 hours in situ.
In some embodiments, two or more active agents can be released from the device at a different rate per 24 hours in situ. For example, an estrogen can be released from the device at an average rate of about 0.01 mg to about 0.1 mg per 24 hours and a progestin can be released from the device at an average rate of about 0.08 mg to about 0.2 mg per 24 hours in situ, or an estrogen can be released from the device at an average rate of about 0.1 mg to about 1 mg per 24 hours in situ and a progestin can be released from the device at an average rate of about 0.05 mg to about 5 mg per 24 hours in situ, or an estrogen can be released from the device at an average rate of about 0.05 mg to about 5 mg per 24 hours in situ and a progestin can be released from the device at an average rate of about 1 mg to about 100 mg per 24 hours in situ.
The release rate can be measured in vitro using, e.g., the USP Apparatus Paddle 2 method. The active agent(s) can be assayed by methods known in the art, e.g., by HPLC.
In some embodiments of the present invention, active agent(s) is/are released from the intravaginal device at a steady rate for up to about 1 month or about 30 days after administration to a female, for up to about 25 days after administration to a female, for up to about 21 days after administration to a female, for up to about 15 days after administration to a female, for up to about 10 days after administration to a female, for up to about 7 days after administration to a female, or for up to about 4 days after administration to a female.
As used herein, a "steady rate" is a release rate that does not vary by an amount greater than 70% of the amount of active agent released per 24 hours in situ, by an amount greater than 60% of the amount of active agent released per 24 hours in situ, by an amount greater than 50% of the amount of active agent released per 24 hours in situ, by an amount greater than 40%) of the amount of active agent released per 24 hours in situ, by an amount greater than 30%> of the amount of active agent released per 24 hours in situ, by an amount greater than 20% of the amount of active agent released per 24 hours in situ, by an amount greater than 10% of the amount of active agent released per 24 hours in situ, or by an amount greater than 5% of the amount of active agent released per 24 hours in situ In some embodiments, the active agent is a progestin with a steady release rate of active agent in situ of about 80 μg to about 200 μg per 24 hours, about 90 μg to about 150 μg per 24 hours, about 90 μg to about 125 μg per 24 hours, or about 95 μg to about 120 μg per 24 hours.
In some embodiments, the active agent includes an estrogen with a steady release rate of active agent in situ of about 10 μg to about 100 μg per 24 hours, about 10 μg to about 80 μg per 24 hours, about 10 μg to about 60 μg per 24 hours, about 10 μg to about 40 μg per 24 hours, about 10 g to about 20 μg per 24 hours, or about 10 μg to about 15 μg per 24 hours.
Use of an intravaginal drug delivery device that includes progestin without an estrogen has advantages over combined progestin/estrogen devices. Some women are unable to tolerate estrogen. For example, women that are breast feeding are unable to take contraceptives that include estrogen. For such women, use of an intravaginal drug delivery device that includes only a progestin would offer a safe solution to the desire to have effective birth control while being unable to take estrogen containing formulations.
The following examples are included to demonstrate preferred embodiments of the invention. It should be appreciated by those of skill in the art that the techniques disclosed in the examples which follow represent techniques discovered by the inventor to function well in the practice of the invention, and thus can be considered to constitute preferred modes for its practice. However, those of skill in the art should, in light of the present disclosure, appreciate that many changes can be made in the specific embodiments which are disclosed and still obtain a like or similar result without departing from the spirit and scope of the invention.
EXAMPLE 1
A progestin and an estrogen are embedded into an ethylene vinyl acetate (EVA) matrix using a melt extruder, using the levels provided in formulation Table 1 below:
Material % Amount
Progestin 0.175 2.520
Estrogen 0.021875 0.315
EVA 99.803125 1,437.165
Total 100 1,440
TABLE 1
The composition is extruded as a flat monolithic sheet that and provides surface area necessary for sustained release of both drug substances over a period of 21 days when measured by drug release in a volumetric flask in pH 7.4 phosphate buffer. EXAMPLE 2
A progestin was embedded into an ethylene vinyl acetate (EVA) matrix using a melt extruder, using the levels provided in formulation Table 1 below:
Material % Amount
Progestin 0.175 2.52
EVA 99.825 1,437.48
Total 100 1,440
TABLE 1
The composition is extruded and molded into a ring. The resulting device is an uncoated ring of progesterone in an EVA matrix. The ring delivered the progestin over a period of 21 days when measured by drug release in a volumetric flask in pH 7.4 phosphate buffer.
EXAMPLE 3
A progestin and an estrogen are embedded into an ethylene vinyl acetate (EVA) matrix using a melt extruder. Additional pore forming agents were incorporated using the levels provided in formulation Table 2 below:
Material % Amount
Progestin 0.175000 2.520
Estrogen 0.021875 0.315
Povidone K 29/32 10.000000 144.000
EVA 89.803125 1,293.165
Total 100 1,440
TABLE 2
The composition is extruded as a flat monolithic sheet that and provides surface area necessary for sustained release of both drug substances over a period of 21 days when measured by drug release in a volumetric flask in pH 7.4 phosphate buffer.
EXAMPLE 4
A progestin and estrogen are embedded into an ethylene vinyl acetate (EVA) matrix using a melt extruder. Additional pore forming agents were incorporated using the levels provided in formulation Table 3 below:
Material % Amount
Progestin 1.500 21.6 Estrogen 0.1875 2.7
Povidone K 29/32 10.0000 144.0
EVA 88.3125 1,271.7
Total 100 1,440.0
TABLE 3
The composition is extruded as a flat monolithic sheet that and provides surface area necessary for sustained release of both drug substances over a period of 21 days when measured by drug release in a volumetric flask in pH 7.4 phosphate buffer.
In this patent, certain U.S. patents, U.S. patent applications, and other materials (e.g., articles) have been incorporated by reference. The text of such U.S. patents, U.S. patent applications, and other materials is, however, only incorporated by reference to the extent that no conflict exists between such text and the other statements and drawings set forth herein. In the event of such conflict, then any such conflicting text in such incorporated by reference U.S.
patents, U.S. patent applications, and other materials is specifically not incorporated by reference in this patent.
Further modifications and alternative embodiments of various aspects of the invention will be apparent to those skilled in the art in view of this description. Accordingly, this description is to be construed as illustrative only and is for the purpose of teaching those skilled in the art the general manner of carrying out the invention. It is to be understood that the forms of the invention shown and described herein are to be taken as examples of embodiments. Elements and materials may be substituted for those illustrated and described herein, parts and processes maybe reversed, and certain features of the invention maybe utilized independently, all as would be apparent to one skilled in the art after having the benefit of this description of the invention. Changes may be made in the elements described herein without departing from the spirit and scope of the invention as described in the following claims.

Claims

WHAT IS CLAIMED IS:
An intravaginal drag delivery device comprising: an uncoated thermoplastic matrix; and a progestin dispersed in the thermoplastic matrix.
The device of claim 1, wherein the progestin compound is etonogestrel.
The device of claim 1, wherein the progestin compound is levonorgestrel.
The device of claim 1, wherein the thermoplastic matrix further comprises an estrogen compound dispersed in the thermoplastic matrix.
The device of claim 4, wherein the estrogen compound is ethinylestradiol.
The device of claim 4, wherein the estrogen compound comprises a nitrated estrogen derivative havin the structure:
Figure imgf000021_0001
where ¾ is hydrogen, C C8 alkyl, cycloalkyl, or Ci-C8 acyl;
R2 is hydrogen or Q-Q alkyl;
R3 is hydrogen, hydroxy or Ci-C8 alkyl;
R4 is hydrogen or CrC8 alkyl;
where each R5 and R6 is, independently, hydrogen or nitrate; and wherein at least one of R5 and R6 is a nitrate group. 7. The device of claim 1, wherein the thermoplastic matrix comprises an ethylene vinyl acetate copolymer.
8. The device of claim 1, wherein the thermoplastic matrix comprises one or more hydrophilic matrix materials. 9. The device of claim 1, wherein the thermoplastic matrix comprises one or more
hydrophobic matrix materials.
10. The device of claim 1, wherein the thermoplastic matrix comprises an ethyl vinyl acetate copolymer and one or more hydrophilic matrix materials.
11. The device of claim 1 , wherein the device has a substantially annular form.
12. The device of claim 1, wherein the thermoplastic matrix further comprises a pore forming component.
13. The device of claim 1, wherein the thermoplastic matrix further comprises a
biodegradable polymer.
14. The device of claim 1, wherein the device delivers an effective amount of the progestin for at least 30 days.
15. The device of claim 1, wherein the thermoplastic matrix further comprises one or more antifungal compounds. 16. The device of claim 1, wherein the thermoplastic matrix further comprises one or more antibiotic compounds.
17. The device of claim 1 , wherein the thermoplastic matrix further comprises one or more antiprogestin compounds.
18. A method of making an intravaginal drug delivery device comprising: forming a mixture of a thermoplastic polymer and a progestin; heating the thermoplastic polymer/progestin mixture such that at least a portion of the thermoplastic polymer is softened or melted to form a heated mixture of thermoplastic polymer and progestin; and permitting the heated mixture to solidify as a solid mass.
19. The method of claim 18, wherein the progestin compound is etonogestrel.
20. The method of claim 18, wherein the progestin compound is levonorgestrel.
21. The method of claim 18, wherein heated mixture is placed in a mold to form the solid mass.
22. The method of claim 18, further comprising blending an estrogen compound with the progestin and the thermoplastic polymer.
23. The method of claim 22, wherein the estrogen compound is ethinylestradiol.
24. The method of claim 22, wherein the estrogen compound comprises a nitrated estrogen derivative having the structure:
Figure imgf000023_0001
where ¾ is hydrogen, C C8 alkyl, cycloalkyl, or Ci-C8 acyl;
R2 is hydrogen or Ci-C8 alkyl;
R3 is hydrogen, hydroxy or Ci-Cs alkyl;
R4 is hydrogen or Ci-C8 alkyl;
where each R5 and R6 is, independently, hydrogen or nitrate; and wherein at least one of R5 and R6 is a nitrate group.
25. The method of claim 18, wherein thermoplastic polymer comprises an ethyl vinyl copolymer.
26. The method of claim 18, wherein thermoplastic matrix comprises an ethyl vinyl
copolymer and a hydrophilic polymer.
27. The method of claim 18, wherein the thermoplastic matrix comprises one or more
hydrophobic matrix materials. 28. The method of claim 18, wherein the thermoplastic matrix further comprises a pore forming component.
29. The method of claim 18, wherein the thermoplastic matrix further comprises a
biodegradable polymer.
30. The method of claim 18, wherein the device delivers an effective amount of the progestin for at least 30 days.
31. The method of claim 18, wherein the thermoplastic matrix further comprises one or more antifungal compounds.
32. The method of claim 18, wherein the thermoplastic matrix further comprises one or more antibiotic compounds. 33. The method of claim 18, wherein the thermoplastic matrix further comprises one or more antiprogestin compounds.
34. An intravaginal drug delivery device made by the method comprising: forming a mixture of a thermoplastic polymer and a progestin; heating the thermoplastic polymer/progestin mixture such that at least a portion of the thermoplastic polymer is softened or melted to form a heated mixture of thermoplastic polymer and progestin; and permitting the heated mixture to solidify as a solid mass; wherein the device comprises the progestin dispersed in an uncoated thermoplastic matrix.
35. The device of claim 34, wherein the progestin compound is etonogestrel.
36. The device of claim 34, wherein the progestin compound is levonorgestrel.
37. The device of claim 34, wherein the thermoplastic matrix further comprises an estrogen compound dispersed in the thermoplastic matrix.
38. The device of claim 37, wherein the estrogen compound is ethinylestradiol.
39. The device of claim 37, wherein the estrogen compound comprises a nitrated estrogen derivative having the structure:
Figure imgf000025_0001
where ¾ is hydrogen, Q-Cs alkyl, cycloalkyl, or Q-Q acyl;
R2 is hydrogen or C Q alkyl;
R3 is hydrogen, hydroxy or C C8 alkyl;
R4 is hydrogen or CpC8 alkyl;
where each R5 and R6 is, independently, hydrogen or nitrate; and wherein at least one of R5 and R6 is a nitrate group.
40. The device of claim 34, wherein the thermoplastic matrix comprises an ethylene vinyl acetate copolymer. 41. The device of claim 34, wherein the thermoplastic matrix comprises one or more
hydrophilic matrix materials.
42. The device of claim 34, wherein the thermoplastic matrix comprises one or more hydrophobic matrix materials. 43. The device of claim 34, wherein the thermoplastic matrix comprises an ethyl vinyl acetate copolymer and one or more hydrophilic matrix materials.
44. The device of claim 34, wherein the device has a substantially annular form. 45. The device of claim 34, wherein the thermoplastic matrix further comprises a pore
forming component.
46. The device of claim 34, wherein the thermoplastic matrix further comprises a
biodegradable polymer.
47. The device of claim 34, wherein the device delivers an effective amount of the progestin for at least 30 days.
48. The device of claim 34, wherein the thermoplastic matrix further comprises one or more antifungal compounds.
49. The device of claim 34, wherein the thermoplastic matrix further comprises one or more antibiotic compounds. 50. The device of claim 34, wherein the thermoplastic matrix further comprises one or more antiprogestin compounds.
51. A method of producing a contraceptive state in a subject comprising positioning an
intravaginal drug delivery device in the vagina or uterus of a female, wherein the intravaginal drug delivery device comprises an uncoated thermoplastic matrix, and a progestin dispersed in the thermoplastic matrix.
The method of claim 51, wherein the progestin compound is etonogestrel.
53. The method of claim 51 , wherein the progestin compound is levonorgestrel.
54. The method of claim 51 , wherein the device further comprises an estrogen dispersed in the thermoplastic matrix..
55. The method of claim 54, wherein the estrogen compound is ethinylestradiol.
56. The method of claim 54, wherein the estrogen compound comprises a nitrated estrogen derivative having the structure:
Figure imgf000027_0001
where ¾ is hydrogen, Q-Cs alkyl, cycloalkyl, or Q-Q acyl;
R2 is hydrogen or Ci-C8 alkyl;
R3 is hydrogen, hydroxy or C C8 alkyl;
R4 is hydrogen or Q-Q alkyl;
where each R5 and R6 is, independently, hydrogen or nitrate; and wherein at least one of R5 and R6 is a nitrate group.
57. The method of claim 51 , wherein the thermoplastic matrix comprises an ethylene vinyl acetate copolymer.
58. The method of claim 51 , wherein the thermoplastic matrix comprises one or more hydrophilic matrix materials.
59. The method of claim 51 , wherein the thermoplastic matrix comprises one or more hydrophobic matrix materials.
60. The method of claim 51 , wherein the thermoplastic matrix comprises an ethyl vinyl acetate copolymer and one or more hydrophilic matrix materials.
61. The method of claim 51 , wherein the device has a substantially annular form.
62. The method of claim 51 , wherein the thermoplastic matrix further comprises a pore
forming component.
63. The method of claim 51 , wherein the thermoplastic matrix further comprises a
biodegradable polymer.
64. The method of claim 51, further comprising delivering an effective amount of the
progestin to the subject for at least 30 days.
65. The method of claim 51 , wherein the thermoplastic matrix further comprises one or more antifungal compounds. 66. The method of claim 51 , wherein the thermoplastic matrix further comprises one or more antibiotic compounds.
67. The method of claim 51 , wherein the thermoplastic matrix further comprises one or more antiprogestin compounds.
68. An intravaginal drug delivery device comprising: a thermoplastic matrix, a progestin dispersed in the thermoplastic matrix; wherein the concentration of progestin dispersed in the thermoplastic matrix is greater than 6 times the saturation concentration for the progestin in the thermoplastic matrix; and an estrogen dispersed in the thermoplastic matrix.
69. The intravaginal drug delivery device of claim 68, wherein the thermoplastic matrix comprises an ethylene vinyl acetate copolymer.
70. The intravaginal drug delivery device of claim 68, wherein the thermoplastic matrix has a substantially annular form.
71. The intravaginal drug delivery device of claim 68, wherein the progestin compound is etonogestrel and the estrogen compound ethinylestradiol.
72. The intravaginal drug delivery device of claim 68, wherein the thermoplastic matrix further comprises a pore forming component. 73. The intravaginal drug delivery device of claim 68, wherein the thermoplastic matrix further comprises a biodegradable polymer.
74. The intravaginal drug delivery device of claim 68, wherein the thermoplastic matrix further comprises one or more hydrophilic matrix materials.
75. An intravaginal drug delivery device comprising: a thermoplastic matrix, a progestin dispersed in the thermoplastic matrix; and an estrogen dispersed in the thermoplastic matrix; wherein the thermoplastic matrix has a non-annular geometry that allows controlled release of the progestin and the estrogen over a predetermined number of days.
76. The intravaginal drug delivery device of claim 75, wherein the thermoplastic matrix comprises an ethylene vinyl acetate copolymer. 77. The intravaginal drug delivery device of claim 75, wherein the progestin compound is etonogestrel and the estrogen compound ethinylestradiol.
78. The intravaginal drug delivery device of claim 75, wherein the thermoplastic matrix further comprises a pore forming component.
79. The intravaginal drug delivery device of claim 75, wherem the thermoplastic matrix further comprises a biodegradable polymer. 80. The intravaginal drug delivery device of claim 75, wherein the thermoplastic matrix further comprises one or more hydrophilic matrix materials.
81. The intravaginal drug delivery device of claim 75, wherein the thermoplastic matrix has a geometry in the form of a strand of geometrically shaped segments linked together.
82. The intravaginal drug delivery device of claim 75, wherein the thermoplastic matrix has a geometry in the form of a half torus.
PCT/US2011/030222 2010-03-28 2011-03-28 Intravaginal drug delivery device WO2011126810A2 (en)

Priority Applications (8)

Application Number Priority Date Filing Date Title
RU2012146080A RU2648827C2 (en) 2010-03-28 2011-03-28 Intravaginal drug delivery device
CN2011800219738A CN103025320A (en) 2010-03-28 2011-03-28 Intravaginal drug delivery device
CA2798034A CA2798034A1 (en) 2010-03-28 2011-03-28 Intravaginal drug delivery device
JP2013502703A JP5813093B2 (en) 2010-03-28 2011-03-28 Intravaginal drug delivery device
AU2011238710A AU2011238710B2 (en) 2010-03-28 2011-03-28 Intravaginal drug delivery device
KR1020127028157A KR101828619B1 (en) 2010-03-28 2011-03-28 Intravaginal drug delivery device
EP11766436.7A EP2552426A4 (en) 2010-03-28 2011-03-28 Intravaginal drug delivery device
ZA2012/08185A ZA201208185B (en) 2010-03-28 2012-10-29 Intravaginall drug delivery device

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US31837610P 2010-03-28 2010-03-28
US61/318,376 2010-03-28

Publications (2)

Publication Number Publication Date
WO2011126810A2 true WO2011126810A2 (en) 2011-10-13
WO2011126810A3 WO2011126810A3 (en) 2012-02-23

Family

ID=44656773

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2011/030222 WO2011126810A2 (en) 2010-03-28 2011-03-28 Intravaginal drug delivery device

Country Status (10)

Country Link
US (1) US20110236462A1 (en)
EP (1) EP2552426A4 (en)
JP (1) JP5813093B2 (en)
KR (1) KR101828619B1 (en)
CN (1) CN103025320A (en)
AU (1) AU2011238710B2 (en)
CA (1) CA2798034A1 (en)
RU (1) RU2648827C2 (en)
WO (1) WO2011126810A2 (en)
ZA (1) ZA201208185B (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8580294B2 (en) 2010-10-19 2013-11-12 International Partnership For Microbicides Platinum-catalyzed intravaginal rings
TWI615155B (en) * 2011-11-01 2018-02-21 拜耳股份有限公司 Osmotically active vaginal delivery system
US10137031B2 (en) 2013-11-14 2018-11-27 International Partnership For Microbicides, Inc. Combination therapy intravaginal rings
EP3125964B1 (en) * 2014-04-01 2024-07-24 Poly-Med Inc. Contraceptive and related device
JP6529583B2 (en) * 2014-06-28 2019-06-12 ラボラトリオス アンドロマコ エス．エー．Ｌａｂｏｒａｔｏｒｉｏｓ Ａｎｄｒｏｍａｃｏ Ｓ．Ａ． A fixed vaginal suppository containing a long lasting, sustained release progesterone useful for preterm birth prevention
WO2016120402A1 (en) * 2015-01-30 2016-08-04 Ligalli B.V. Vaginal drug delivery device
KR102580593B1 (en) * 2017-07-08 2023-09-20 헤라 헬스 솔루션즈 인크. Bioerosive drug delivery implant
KR20220101660A (en) * 2019-11-12 2022-07-19 폴리-메드, 인코포레이티드 contraceptive medical device

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5788980A (en) 1995-11-01 1998-08-04 Roussel Uclaf Intravaginal drug delivery device
WO2001037770A1 (en) 1999-11-24 2001-05-31 Agile Therapeutics, Inc. Improved transdermal contraceptive delivery system and process
WO2005002482A1 (en) 2002-05-23 2005-01-13 Agile Therapeutics, Inc. Transdermal hormone delivery system: compositions and methods
US20050118244A1 (en) 2001-12-01 2005-06-02 Lts Lohmann Therapie-System Ag Transmittal therapeutic systems containing steroid hormones and propylene glycol monocaprylate
US7045145B1 (en) 1999-11-24 2006-05-16 Agile Therapeutics, Inc. Transdermal contraceptive delivery system and process
US20070196433A1 (en) 2003-04-29 2007-08-23 The Massachusetts General Hospital Corporation Methods and devices for the sustained release of multiple drugs
WO2010019226A1 (en) 2008-08-12 2010-02-18 Teva Women's Health, Inc. Intravaginal devices with a rigid support, methods of making, and uses thereof
WO2012024461A2 (en) 2010-08-20 2012-02-23 Teva Women's Health, Inc. Intravaginal devices, methods of making, and uses thereof

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3545439A (en) * 1968-01-04 1970-12-08 Upjohn Co Medicated devices and methods
US3948254A (en) * 1971-11-08 1976-04-06 Alza Corporation Novel drug delivery device
US3995634A (en) * 1975-12-02 1976-12-07 The Procter & Gamble Company Vaginal cavity dispensing means and method
US3995633A (en) * 1975-12-02 1976-12-07 The Procter & Gamble Company Vaginal Medicament dispensing device
US4402695A (en) * 1980-01-21 1983-09-06 Alza Corporation Device for delivering agent in vagina
US4968507A (en) * 1984-06-20 1990-11-06 Merck & Co., Inc. Controlled porosity osmotic pump
US5554603A (en) * 1993-09-17 1996-09-10 The United States Of America As Represented By The Department Of Health And Human Services Orally active derivatives of 1,3,5(10)-estratriene
US5562654A (en) * 1994-10-28 1996-10-08 University Of Kentucky Research Foundation Time-released delivery system
US5906830A (en) * 1995-09-08 1999-05-25 Cygnus, Inc. Supersaturated transdermal drug delivery systems, and methods for manufacturing the same
US5814329A (en) * 1996-11-12 1998-09-29 Polytherapeutics, Inc. Hydrophilic polystyrene graft copolymer vehicle for intravaginal administration of pharmacologically active agents
JPH10279499A (en) * 1997-04-04 1998-10-20 Takeda Chem Ind Ltd Preparation applicable to uterine mucosa
TW358031B (en) * 1997-04-11 1999-05-11 Akze Nobel N V Drug delivery system for 2 or more active substances
NZ528377A (en) * 2001-03-27 2005-05-27 Galen Chemicals Ltd Intravaginal drug delivery devices for the administration of an antimicrobial agent
TWI336627B (en) * 2003-05-23 2011-02-01 Organon Nv Drug delivery system,and use and manufacturing method thereof
US8399013B2 (en) * 2003-06-26 2013-03-19 Poly-Med, Inc. Partially absorbable fiber-reinforced composites for controlled drug delivery
CN100531800C (en) * 2004-03-24 2009-08-26 奥尔加侬股份有限公司 Drug delivery system based on polyethylene vinylacetate copolymers
WO2006013851A1 (en) * 2004-08-03 2006-02-09 Nippon Shinyaku Co., Ltd. Device to be used in body cavity and sustained-release preparation
US7862552B2 (en) * 2005-05-09 2011-01-04 Boston Scientific Scimed, Inc. Medical devices for treating urological and uterine conditions
FR2917886B1 (en) * 2007-06-20 2009-10-30 Nexans Sa ELECTRICAL CONDUCTOR ISOLATED.
CN105581976A (en) * 2007-06-26 2016-05-18 沃纳奇尔科特有限责任公司 Intravaginal drug delivery devices for the delivery of macromolecules and watersoluble drugs
TW200927141A (en) * 2007-11-22 2009-07-01 Bayer Schering Pharma Oy Vaginal delivery system
WO2010054296A2 (en) * 2008-11-07 2010-05-14 Combinent Biomedical Systems, Inc. Devices and methods for treating and/or preventing diseases

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5788980A (en) 1995-11-01 1998-08-04 Roussel Uclaf Intravaginal drug delivery device
WO2001037770A1 (en) 1999-11-24 2001-05-31 Agile Therapeutics, Inc. Improved transdermal contraceptive delivery system and process
US7045145B1 (en) 1999-11-24 2006-05-16 Agile Therapeutics, Inc. Transdermal contraceptive delivery system and process
US20050118244A1 (en) 2001-12-01 2005-06-02 Lts Lohmann Therapie-System Ag Transmittal therapeutic systems containing steroid hormones and propylene glycol monocaprylate
WO2005002482A1 (en) 2002-05-23 2005-01-13 Agile Therapeutics, Inc. Transdermal hormone delivery system: compositions and methods
US20070196433A1 (en) 2003-04-29 2007-08-23 The Massachusetts General Hospital Corporation Methods and devices for the sustained release of multiple drugs
WO2010019226A1 (en) 2008-08-12 2010-02-18 Teva Women's Health, Inc. Intravaginal devices with a rigid support, methods of making, and uses thereof
WO2012024461A2 (en) 2010-08-20 2012-02-23 Teva Women's Health, Inc. Intravaginal devices, methods of making, and uses thereof

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of EP2552426A4

Also Published As

Publication number Publication date
JP5813093B2 (en) 2015-11-17
RU2648827C2 (en) 2018-03-28
RU2012146080A (en) 2014-05-10
KR20130067259A (en) 2013-06-21
CN103025320A (en) 2013-04-03
AU2011238710B2 (en) 2015-08-20
KR101828619B1 (en) 2018-02-12
JP2013523745A (en) 2013-06-17
EP2552426A4 (en) 2014-12-17
WO2011126810A3 (en) 2012-02-23
CA2798034A1 (en) 2011-10-13
EP2552426A2 (en) 2013-02-06
US20110236462A1 (en) 2011-09-29
ZA201208185B (en) 2014-03-26

Similar Documents

Publication Publication Date Title
AU2011238710B2 (en) Intravaginal drug delivery device
AU2011238710A1 (en) Intravaginal drug delivery device
AU2009282496B2 (en) Intravaginal devices with a rigid support, methods of making, and uses thereof
US4402695A (en) Device for delivering agent in vagina
US20180263899A1 (en) Intrauterine delivery system for contraception
RU2607179C2 (en) Intravaginal device for drug delivery
US4629449A (en) Vaginal dispenser for dispensing beneficial hormone
US4961931A (en) Method for the management of hyperplasia
CN101827569B (en) Drug delivery system
US20170319833A1 (en) Intravaginal drug delivery device
CA2524665A1 (en) Drug delivery system
EA018112B1 (en) Vaginal delivery system
CA2872644A1 (en) Formulations and methods for vaginal delivery of antiprogestins
US20190328657A1 (en) Hormonal contraception using a vaginal ring which releases estriol
US8980304B2 (en) Barrel-shaped vaginal ring
CA2948287A1 (en) Formulations and methods for vaginal delivery of antiprogestins
WO2023141198A1 (en) Combination therapy intravaginal rings
JP2024534527A (en) Refillable implantable device for delivering contraceptives - Patent Application 20070229633

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 201180021973.8

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 11766436

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2013502703

Country of ref document: JP

ENP Entry into the national phase

Ref document number: 20127028157

Country of ref document: KR

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2012146080

Country of ref document: RU

Ref document number: 2011766436

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2798034

Country of ref document: CA

ENP Entry into the national phase

Ref document number: 2011238710

Country of ref document: AU

Date of ref document: 20110328

Kind code of ref document: A